These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 17302366)

  • 1. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
    Abed Y; Baz M; Boivin G
    Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
    Abed Y; Nehmé B; Baz M; Boivin G
    Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
    Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
    J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
    Baz M; Abed Y; Boivin G
    Antiviral Res; 2007 May; 74(2):159-62. PubMed ID: 17137644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
    Pizzorno A; Bouhy X; Abed Y; Boivin G
    J Infect Dis; 2011 Jan; 203(1):25-31. PubMed ID: 21148493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
    McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
    J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
    Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
    J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
    Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
    Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
    Choi WS; Jeong JH; Kwon JJ; Ahn SJ; Lloren KKS; Kwon HI; Chae HB; Hwang J; Kim MH; Kim CJ; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
    Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
    Hoffmann A; Schade D; Kirchmair J; Clement B; Sauerbrei A; Schmidtke M
    J Virol Methods; 2016 Nov; 237():192-199. PubMed ID: 27659246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
    Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
    Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
    Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.
    L'Huillier AG; Abed Y; Petty TJ; Cordey S; Thomas Y; Bouhy X; Schibler M; Simon A; Chalandon Y; van Delden C; Zdobnov E; Boquete-Suter P; Boivin G; Kaiser L
    J Infect Dis; 2015 Dec; 212(11):1726-34. PubMed ID: 25985905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.